NCT01808118View on ClinicalTrials.gov

Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

673

Participants

Timeline

Start Date

April 16, 2013

Primary Completion Date

February 21, 2017

Study Completion Date

April 14, 2017

Conditions
Axial Spondyloarthritis
Interventions
BIOLOGICAL

adalimumab

40 mg every other week

BIOLOGICAL

Placebo

every other week

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY